Burgers Leonie E, Siljehult Filip, Ten Brinck Robin M, van Steenbergen Hanna W, Landewé Robert B M, Rantapää-Dahlqvist Solbritt, van der Helm-van Mil Annette H M
Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden.
Rheumatology (Oxford). 2017 Dec 1;56(12):2123-2128. doi: 10.1093/rheumatology/kex324.
Recently a EULAR-taskforce defined arthralgia suspicious for progression to RA, in order to allow inclusion of homogeneous sets of arthralgia patients in clinical studies. This longitudinal study aimed (i) to validate this definition in arthralgia patients in whom rheumatologists felt that imminent RA was more likely than other arthralgias [clinically suspect arthralgia (CSA)], that is, the target population fulfilling the entry criterion, and (ii) to explore the performance in arthralgia patients who were referred to secondary care prior to rheumatological evaluation, hence ignoring the entry criterion.
The definition was assessed in 241 Dutch patients identified with CSA by rheumatologists and 113 patients referred to the Umeå university hospital with recent-onset arthralgia in small joints. The external reference was arthritis development <2 years' follow-up.
CSA patients with a positive definition (⩾3/7 parameters present) had an increased risk for developing arthritis compared with definition-negative CSA patients (hazard ratio = 2.1, 95% CI: 0.9, 4.7). The sensitivity was 84% and the positive predictive value 30%. In arthralgia patients in whom the definition was applied before rheumatological evaluation, a positive definition was neither sensitive (10%) nor predictive (positive predictive value 3%).
The EULAR definition of arthralgia suspicious for progression to RA is sensitive when used to support the rheumatologist's opinion on imminent RA. This validation study shows that the definition, when used as designed, further homogenizes patients that rheumatologists consider at risk for RA. To arrive at a high specificity, the clinical definition needs to be combined with biomarkers.
最近,一个欧洲抗风湿病联盟(EULAR)特别工作组定义了可疑进展为类风湿关节炎(RA)的关节痛,以便在临床研究中纳入同质的关节痛患者群体。这项纵向研究旨在:(i)在风湿病学家认为即将发生RA比其他关节痛更有可能的关节痛患者中(即临床可疑关节痛(CSA))验证该定义,这些患者是符合纳入标准的目标人群;(ii)探讨该定义在风湿病学评估前被转诊至二级医疗机构的关节痛患者中的表现,因此这些患者忽略了纳入标准。
对241例被风湿病学家诊断为CSA的荷兰患者以及113例因小关节近期发作性关节痛而转诊至于默奥大学医院的患者评估该定义。外部参照为随访<2年的关节炎发展情况。
定义阳性(存在≥3/7项参数)的CSA患者与定义阴性的CSA患者相比,发生关节炎的风险增加(风险比=2.1,95%置信区间:0.9,4.7)。敏感性为84%,阳性预测值为30%。在风湿病学评估前应用该定义的关节痛患者中,定义阳性既不敏感(10%)也无预测性(阳性预测值3%)。
EULAR关于可疑进展为RA的关节痛定义在用于支持风湿病学家对即将发生RA的判断时是敏感的。这项验证研究表明,按设计使用该定义可进一步使风湿病学家认为有RA风险的患者同质化。为了达到高特异性,临床定义需要与生物标志物相结合。